Observational studyInternational journal of urology : official journal of the Japanese Urological Association2026
Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON.
Observational study in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stage-specific prognostic value of PSA in prostate cancer: a multicentre KAMU-ON study.World journal of urology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate stage-specific temporal trends in treatment patterns and overall survival (OS) among patients with prostate cancer in a Japanese multicentre cohort.
methodsThis multicentre retrospective cohort study used data from the Kaga Million Uro-Oncology Network (KAMU-ON) registry. Patients diagnosed with prostate cancer between 2010 and 2024 were categorized as localized, nonmetastatic advanced, or metastatic disease. OS was assessed using Kaplan-Meier analyses and multivariable Cox proportional hazards models adjusted for clinically relevant covariates. Additional analyses with follow-up administratively restricted at 48 months were performed.
resultsA total of 7140 patients with defined disease stage and available survival data were included, comprising 5048 patients with localized disease, 1128 with nonmetastatic advanced disease, and 964 with metastatic disease. Treatment patterns changed substantially across diagnostic eras. Survival improvement appeared most evident in metastatic disease, whereas temporal differences were less apparent in nonmetastatic advanced disease. In multivariable Cox analyses, later diagnostic eras were associated with lower hazards of death in the overall cohort (2014-2017: HR 0.90, 95% CI 0.76-1.08; 2018-2024: HR 0.79, 95% CI 0.64-0.98). Formal interaction testing did not demonstrate statistically significant effect modification according to disease stage (p = 0.163).
conclusionsTemporal survival trends in prostate cancer appeared to vary across disease stages in this Japanese multicentre cohort. Survival improvement appeared most evident in metastatic disease, whereas changes were less pronounced in nonmetastatic advanced disease. These findings suggest that therapeutic advances may not uniformly translate into survival gains across prostate cancer disease states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.